We are live on ! Find out more
ACM

AIGH Capital Management Portfolio holdings

AUM $1.59B
1-Year Est. Return 855.46%
This Fund
S&P 500
This Quarter Est. Return
+41.06%
1 Year Est. Return
+855.46%
3 Year Est. Return
+3,007.26%
5 Year Est. Return
+4,204.76%
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$133M
Cap. Flow
+$2.48B
Cap. Flow %
699.83%
Top 10 Hldgs %
60.33%
Holding
53
New
18
Increased
5
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
MXL icon
MaxLinear
MXL
+$17.4M
2
SNDK
Sandisk
SNDK
+$16.4M
3
CSTL icon
Castle Biosciences
CSTL
+$14.4M
4
LUMN icon
Lumen
LUMN
+$12.2M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$10.5M

Top Sells

Rank Stock Value
1
SCPH
scPharmaceuticals
SCPH
+$14.7M
2
LPTH icon
Lightpath Technologies
LPTH
+$12.2M
3
ELVA
Electrovaya
ELVA
+$9.96M
4
BLZE icon
Backblaze
BLZE
+$9.95M
5
VSTM icon
Verastem
VSTM
+$8.31M

Sector Composition

Rank Sector Weight
1 Technology 38.61%
2 Healthcare 31.94%
3 Industrials 5.52%
4 Communication Services 4.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYPD icon
26
PolyPid
PYPD
$92.8M
$3.55M 1%
1,065,128
-128,980
-11% -$447K
RNXT icon
27
RenovoRx
RNXT
$50.5M
$3.32M 0.94%
2,615,193
-852,082
-25% -$1.01M
LRMR icon
28
Larimar Therapeutics
LRMR
$432M
$3.23M 0.91%
+1,000,000
New +$3.75M
ELUT icon
29
Elutia
ELUT
$37.6M
$2.82M 0.79%
3,165,128
-285,897
-8% -$530K
VUZI icon
30
Vuzix
VUZI
$224M
$2.81M 0.79%
+898,648
New +$2.12M
GRCE
31
Grace Therapeutics
GRCE
$34.7M
$2.7M 0.76%
907,217
-221,280
-20% -$694K
IPWR icon
32
Ideal Power
IPWR
$74.2M
$2.58M 0.73%
513,047
-155,576
-23% -$804K
NRXS icon
33
Neuraxis
NRXS
$88.5M
$1.23M 0.35%
400,000
– –
ELVA
34
Electrovaya
ELVA
$481M
$1.13M 0.32%
192,100
-1,963,736
-91% -$9.96M
ARDX icon
35
Ardelyx
ARDX
$988M
$1.09M 0.31%
+198,500
New +$1.08M
BFRI icon
36
Biofrontera
BFRI
$16.3M
$1.03M 0.29%
1,046,050
+71,525
+7% +$64.8K
APRE icon
37
Aprea Therapeutics
APRE
$8.05M
$795K 0.22%
539,300
– –
SMTK
38
SmartKem
SMTK
$3.99M
$714K 0.2%
425,277
-13,408
-3% -$14.9K
ALNT icon
39
Allient
ALNT
$1.92B
– –
-200,000
Closed -$7.26M
AMPG icon
40
AmpliTech
AMPG
$147M
– –
-905,453
Closed -$1.92M
ANGO icon
41
AngioDynamics
ANGO
$649M
– –
-474,488
Closed -$4.71M
BLZE icon
42
Backblaze
BLZE
$1.16B
– –
-1,809,096
Closed -$9.95M
FKWL icon
43
Franklin Wireless
FKWL
$27M
– –
-139,702
Closed -$584K
HRTX icon
44
Heron Therapeutics
HRTX
$92.9M
– –
-3,009,257
Closed -$6.23M
IDN icon
45
Intellicheck
IDN
$79.6M
– –
-154,174
Closed -$831K
INAB icon
46
IN8bio
INAB
$9.64M
– –
-149,895
Closed -$313K
KALA icon
47
KALA BIO
KALA
$14.5M
– –
-6,000
Closed -$1.43M
KPRX icon
48
Kiora Pharmaceuticals
KPRX
$11.7M
– –
-216,345
Closed -$623K
MYO icon
49
Myomo
MYO
$56.2M
– –
-3,555,742
Closed -$7.68M
PHGE icon
50
BiomX
PHGE
$1.85M
– –
-82,471
Closed -$705K
1
2
3

Similar funds

VNT
Vanguard National Trust Malvern, Pennsylvania $1.59B AUM
GWANC
Guardian Wealth Advisors (North Carolina) Raleigh, North Carolina $1.59B AUM 15.17% 1-Year Est. Return
NCL
Nishkama Capital LLC Dorado, Puerto Rico $1.58B AUM 123.32% 1-Year Est. Return
DG
DigitalBridge Group Boca Raton, Florida $1.58B AUM 62.54% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return
LCM
Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
FDCP
Foster Dykema Cabot & Partners Waltham, Massachusetts $1.57B AUM 20.41% 1-Year Est. Return

AIGH Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, AIGH Capital Management held 53 positions worth $355M, up 60% from $222M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

AIGH Capital Management deployed $2.48B of net new capital in Q3 2025, opening 18 new positions and adding to 5 existing holdings. Its largest new stake was MaxLinear: 1,107,504 shares worth $17.8M.

By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Lightpath Technologies, an estimated $12.2M trimmed.

  • AIGH Capital Management's largest Q3 2025 buy was MaxLinear: 1,107,504 shares worth $17.8M.
  • AIGH Capital Management added most to Zevra Therapeutics in Q3 2025, an estimated $3.14M increase.
  • AIGH Capital Management's biggest Q3 2025 reduction was Lightpath Technologies, cutting an estimated $12.2M.
  • AIGH Capital Management fully exited scPharmaceuticals in Q3 2025, selling an estimated $14.7M.
  • AIGH Capital Management's ten largest holdings make up 60% of its $355M portfolio in Q3 2025.
  • AIGH Capital Management opened 18 new positions and closed 15 in Q3 2025.
  • AIGH Capital Management's portfolio value rose 60% quarter-over-quarter to $355M.

Based on AIGH Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.